|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2002-7-30
|
|
pubmed:abstractText |
Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1413-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12147788-Albuminuria,
pubmed-meshheading:12147788-Antihypertensive Agents,
pubmed-meshheading:12147788-Blood Pressure,
pubmed-meshheading:12147788-Diabetic Angiopathies,
pubmed-meshheading:12147788-Diabetic Nephropathies,
pubmed-meshheading:12147788-Diastole,
pubmed-meshheading:12147788-Dose-Response Relationship, Drug,
pubmed-meshheading:12147788-Glomerular Filtration Rate,
pubmed-meshheading:12147788-Humans,
pubmed-meshheading:12147788-Hypertension,
pubmed-meshheading:12147788-Kidney,
pubmed-meshheading:12147788-Losartan,
pubmed-meshheading:12147788-Systole,
pubmed-meshheading:12147788-Time Factors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Optimal dose of losartan for renoprotection in diabetic nephropathy.
|
|
pubmed:affiliation |
Steno Diabetes Center, Copenhagen, Denmark. STAN@dadlnet.dk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
